Search the Newsreel

CorMedix Inc. Revenue Breakdown – NASDAQ:CRMD

CorMedix Inc. (NASDAQ:CRMD) generated $311.71 million USD in revenue last year, with its Drug segment being the top performer, contributing $304.34 million USD. The majority of this revenue, $304.34 million USD, originated from the United States. This marks a significant increase from the previous …

(CRMD) Movement as an Input in Quant Signal Sets

This article analyzes Cormedix Inc. (NASDAQ: CRMD) using quantitative signals, highlighting a weak sentiment across all horizons and supporting a short bias. It identifies an exceptional 89.0:1 risk-reward short setup, targeting a 21.0% downside with minimal risk. The report also outlines distinct AI-generated trading …

CorMedix Inc (CRMD) Institutional Confidence

The article provides an overview of CorMedix Inc.'s institutional confidence score, which stands at 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. Institutional shareholding is 55.17%, a slight decrease from the previous quarter, with Chuck Royce being the largest institutional shareholder. …

CorMedix Inc (CRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates

CorMedix Inc (CRMD) has an earnings forecast score of 8.29, ranking 46th in the Pharmaceuticals industry. Analysts have set an average price target of $20.00, with a consensus "Buy" rating based on 5 analysts. The company's expected revenue for the next quarter is $95.62M, …

CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Analysts

CorMedix Inc (NASDAQ:CRMD) has received a consensus "Moderate Buy" rating from analysts, with six brokerages recommending a buy and two a hold. The average 12-month price target is set at $14.86. This follows the company's strong quarterly results, including an EPS of $0.43 against …

CorMedix (NASDAQ:CRMD) Stock Price Down 5.9% - Time to Sell?

CRMD's Growth Story Expands Beyond DefenCath Into New Trends

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why

Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?

A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance

CorMedix (CRMD) Q1 Earnings Margin Surge Tests Bearish Narratives

Dialysis drug DefenCath drives $97.5M in Q1 sales as CorMedix lifts 2026 targets

CORMEDIX ($CRMD) Releases Q1 2026 Earnings

Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Earnings call transcript: CorMedix Q1 2026 revenue beats, stock surges

CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

What CorMedix says before the bell May 14: earnings and update

How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets

Biotech CorMedix sets March 5 call on 2025 results, corporate update

Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?

CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%

Why CorMedix (CRMD) Is Down 35.4% After Cutting 2026 Guidance And Revamping Its Leadership Structure